CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
Frequently asked questions
What sector does CellaVision AB (CEVI) operate in?
CellaVision AB belongs to the Healthcare sector and operates in the Medical Devices industry.
What is CellaVision AB (CEVI) current stock price?
As of the latest data, CellaVision AB stock price is SEK 152.40, with a previous close of SEK 152.40.
What is CellaVision AB (CEVI) current market capitalization?
CellaVision AB market cap is approximately 3.63 billion.
What is CellaVision AB (CEVI) Earnings Per Share (EPS)?
The trailing EPS is SEK 5.61, and the forward EPS is SEK 7.16.
What is CellaVision AB (CEVI) Price-to-Earnings (P/E) ratio?
CellaVision AB current P/E ratio is 27.17, with a forward P/E of 21.28.
What is CellaVision AB (CEVI) EBITDA?
CellaVision AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 39.92 million.
Does CellaVision AB (CEVI) pay dividends?
Yes. CellaVision AB pays annual dividends with an annualized yield of 1.8% and an estimated annual payout of SEK 2.75 per share.
When is the next ex-dividend date for CellaVision AB (CEVI)?
The next ex-dividend date is scheduled for April 29, 2027.
How did CellaVision AB (CEVI) perform in its most recent earnings report?
In the last report (June 30, 2026), CellaVision AB posted an EPS surprise of -41.98% and a revenue surprise of -12.87%.
What is CellaVision AB (CEVI) beta (volatility) score?
CellaVision AB has a beta of 0.962, meaning its volatility is roughly in line with the market.
